Approval · Notice of Compliance 18029 · 2016
TASIGNA: Notice of Compliance 18029
Issued April 20, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18029
- Date
- April 20, 2016
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update carton labels due to new carton size/format for the 200 mg capsules pack size; update text on the 150 mg capsules labels to maintain consistency; and to implement editorial changes to the text on the 150 mg and 200 mg capsule foil labels
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TASIGNA | Not yet assigned | — |